Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Miconazole: a historical perspective.

Annette W Fothergill1

  • 1Department of Pathology, University of Texas Health Science Center, San Antonio, TX 78229, USA. fothergill@uthscsa.edu

Expert Review of Anti-Infective Therapy
|April 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

mBio·2018
Same author

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Antimicrobial agents and chemotherapy·2016
Same author

Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Virulence·2016
Same author

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata.

International journal of antimicrobial agents·2016
Same author

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Antimicrobial agents and chemotherapy·2016
Same author

Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Journal of clinical microbiology·2016
Same journal

Study of prescription-indication of antivirals for herpesviruses in a Colombian population: a cross-sectional study.

Expert review of anti-infective therapy·2026
Same journal

Effectiveness and safety of eravacycline-based regimens for resistant <i>Acinetobacter baumannii</i> infections: a systematic review and meta-analysis.

Expert review of anti-infective therapy·2026
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
Same journal

Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disease as an early neuroinflammatory state.

Expert review of anti-infective therapy·2026
Same journal

The endocarditis team: a review.

Expert review of anti-infective therapy·2026
Same journal

Synergistic antifungal effects and potential mode of action of crisaborole combined with azoles against drug-resistant <i>Candida albicans</i>.

Expert review of anti-infective therapy·2026
See all related articles

Miconazole, an antifungal imidazole, effectively treats superficial fungal infections through two mechanisms: inhibiting ergosterol synthesis and causing peroxide accumulation. Yeast fungi remain susceptible, making it a leading treatment for vaginal candidiasis.

Area of Science:

  • Mycology
  • Pharmacology
  • Dermatology

Background:

  • Miconazole, an imidazole antifungal, has a 30-year history of treating superficial and cutaneous diseases.
  • It is distinguished by a dual mechanism of action, unlike other azoles.
  • Vaginal candidiasis remains a common indication for miconazole prescription.

Purpose of the Study:

  • To review the mechanisms of action of miconazole.
  • To examine the antifungal susceptibility patterns of miconazole.
  • To highlight the continued relevance of miconazole in treating vaginal candidiasis.

Main Methods:

  • Literature review of miconazole's pharmacological properties.
  • Analysis of antifungal susceptibility data for miconazole.
  • Clinical prescribing trends for miconazole.

Related Experiment Videos

Main Results:

  • Miconazole inhibits ergosterol synthesis and also disrupts cellular integrity via peroxide accumulation.
  • Yeast fungi demonstrate sustained susceptibility to miconazole, even after repeated exposure.
  • Miconazole remains a primary antifungal agent for vaginal candidiasis.

Conclusions:

  • Miconazole's dual action contributes to its efficacy and sustained activity against fungi.
  • Its effectiveness and safety profile support its continued use in clinical practice.
  • Miconazole remains a cornerstone therapy for superficial fungal infections, particularly vaginal candidiasis.